Trilaciclib

Introduction: What is Trilaciclib?

Trilaciclib is a medication primarily used in the treatment of certain types of cancer. It is classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor, which helps protect hematopoietic stem and progenitor cells from chemotherapy-induced damage in the bone marrow. It is often used in combination with other cancer therapies to enhance their effectiveness and reduce side effects.

Uses of Trilaciclib

Trilaciclib has been approved for use in extensive-stage small cell lung cancer (ES-SCLC) who have not received prior treatment for their ES-SCLC and are receiving platinum-based chemotherapy (with or without etoposide) or topotecan. The medication is designed to protect bone marrow function during chemotherapy, which can help reduce the risk of complications such as low blood cell counts.

How Does It Work?

Trilaciclib works by inhibiting specific proteins that are essential for cell division and growth. In simpler terms, it slows down the process that allows cancer cells to multiply. By blocking these proteins, Trilaciclib helps to keep cancer cells from growing too quickly, making it easier for other treatments, like chemotherapy, to be effective. Additionally, it helps to preserve healthy bone marrow cells, which are crucial for producing blood cells.

Dosage and Administration

The standard dosage of Trilaciclib for adults is typically administered as an intravenous (IV) infusion. The recommended dose is 240 mg, given over a period of 30 minutes, and it is usually administered on the same day as chemotherapy. Trilaciclib is approved only for adult patients. Trilaciclib is not available in tablet form and is only given through injection.

Side Effects of Trilaciclib

Like all medications, Trilaciclib can cause side effects. Common side effects include:

• Fatigue
• Nausea
• Vomiting
• Diarrhea
• Decreased appetite

Serious side effects may include:

• Severe allergic reactions (rash, itching, swelling)
• Infusion-related reactions (e.g., flushing, dysgeusia)
• Interstitial lung disease (ILD)/pneumonitis
• Myelosuppression (though reduced compared to chemotherapy alone; anemia, neutropenia, thrombocytopenia)
• Infections due to low white blood cell counts

Patients should report any unusual symptoms to their healthcare provider promptly.

Drug Interactions

Trilaciclib may interact with other medications, which can affect how it works or increase the risk of side effects. Major drug interactions include:

• Strong CYP3A inhibitors (e.g., ketoconazole; may increase trilaciclib exposure)
• Strong CYP3A inducers (e.g., rifampin; may decrease exposure)
• Substrates of OATP1B1/3 or BCRP (e.g., rosuvastatin, methotrexate; trilaciclib may increase levels)

It is crucial to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.

Benefits of Trilaciclib

The primary benefit of Trilaciclib is its ability to protect bone marrow function during chemotherapy, which can lead to fewer side effects and complications. By preserving healthy blood cell production, it helps patients maintain better overall health during cancer treatment. Additionally, Trilaciclib may enhance the effectiveness of chemotherapy, potentially leading to improved treatment outcomes.

Contraindications of Trilaciclib

Certain individuals should avoid using Trilaciclib. Contraindications include:

• No formal contraindications
• Avoid in pregnancy (may cause fetal harm; verify negative pregnancy test)
• Use caution in severe hepatic impairment (has not been studied)

Always consult a healthcare provider to determine if Trilaciclib is appropriate for your specific situation.

Precautions and Warnings

Before starting Trilaciclib, patients should undergo specific lab tests to assess their overall health and liver function. It is essential to monitor blood cell counts regularly during treatment to detect any potential issues early. Patients should also be aware of signs of infection or unusual bleeding and report these to their healthcare provider immediately.

• Monitor for ILD/pneumonitis (withhold if suspected)
• Embryo-fetal toxicity: Advise contraception

FAQs

1. What is Trilaciclib used for? Trilaciclib is used to protect bone marrow function in patients with small cell lung cancer undergoing chemotherapy.
2. How is Trilaciclib administered? Trilaciclib is given as an intravenous infusion, typically on the same day as chemotherapy.
3. What are the common side effects? Common side effects include fatigue, nausea, vomiting, diarrhea, and decreased appetite.
4. Can Trilaciclib be used in children? Trilaciclib is not approved for use in children; safety and efficacy have not been established.
5. What should I do if I miss a dose? If you miss a dose, contact your healthcare provider for guidance on what to do next.
6. Are there any serious side effects? Yes, serious side effects can include severe allergic reactions and low blood cell counts.
7. Can I take other medications with Trilaciclib? Inform your healthcare provider about all the medications you are taking to avoid potential interactions.
8. Is Trilaciclib safe during pregnancy? No, Trilaciclib is not recommended for use during pregnancy or breastfeeding.
9. How does Trilaciclib work? Trilaciclib inhibits proteins that allow cancer cells to grow, slowing down their multiplication.
10. What should I monitor while on Trilaciclib? Regular blood tests to monitor blood cell counts and liver function tests as clinically indicated.

Brand Names

Trilaciclib is marketed under the brand name Cosela (G1 Therapeutics). It is important to note that brand names may vary by region and manufacturer.

Conclusion

Trilaciclib plays a significant role in the treatment of small cell lung cancer by protecting bone marrow function during chemotherapy. Its ability to enhance the effectiveness of cancer treatments while minimizing side effects makes it a valuable option for patients. As with any medication, it is essential to discuss its use with a healthcare provider to ensure it is appropriate for your individual health needs.